Psychopharmacology: A mental health professional’s guide to commonly used medications

Description

This concise, accessible text is suitable for all trainee and registered health professionals who require knowledge and understanding of drugs used in the treatment of mental health conditions. Introductory material provides a background on psychotropic drugs, the etiology of mental illness, and brief notes on common non-pharmacological interventional options. It also examines biochemical and neurodevelopmental theories and the link to the pathophysiology of mental illness, as well as clinical decision making. The central chapters of the book provide comprehensive coverage of all the major medications used in mental health. Each focuses on a specific class of drug, detailing the most commonly used medicines, including side effects, average doses, contra-indications, and clinical management interventions that may be required. At the end of each chapter, a series of review questions enable readers to review their learning, and theory is clearly related to practice throughout. Cover......Page 1 Title page......Page 3 Copyright information......Page 4 Table of contents......Page 5 Meet the author......Page 8 Acknowledgments......Page 9 Foreword......Page 10 What the reviewers say......Page 12 Introduction......Page 15 Learning features......Page 16 1.1 Introduction......Page 18 1.2 Aetiology of mental illness......Page 20 Neurons and neurotransmitters......Page 21 1.4 Clinical decision-making in practice and medicine management......Page 25 2.1 Introduction......Page 33 Glutamate hypothesis......Page 34 Dopamine hypothesis......Page 35 Typical antipsychotics (first-generation antipsychotics)......Page 37 Atypical antipsychotics (second-generation antipsychotics)......Page 38 Rapid tranquillisation......Page 39 Antipsychotic drugs in depot preparation......Page 45 Prescribing antipsychotic drugs to smokers......Page 47 Extrapyramidal side effects......Page 48 Akathisia......Page 49 Drug-induced parkinsonism......Page 50 Tardive dyskinesia......Page 51 Management of tardive dyskinesia......Page 52 Muscarinic 1 receptor block......Page 54 Cardiovascular effects......Page 56 Gender......Page 59 Other contributing factors to weight gain in people with mental illness......Page 60 Weight gain monitoring and management......Page 62 Endocrine adverse effects......Page 63 Allergic and dermatological effects......Page 65 Haematological adverse effects......Page 66 Obligatory monitoring for clozapine therapy......Page 67 Other adverse effects of clozapine......Page 68 2.5 Medication adherence in mental health settings......Page 69 3.1 Introduction......Page 75 Monoamine theory of depression......Page 76 3.3 Dose and administration......Page 77 Selective serotonin reuptake inhibitors......Page 83 Adverse effects and management......Page 84 Adverse effects and management......Page 85 Tetracyclic (noradrenergic and specific serotonergic antidepressants)......Page 86 Aminoketone (bupropion)......Page 87 Monoamine oxidase inhibitors......Page 88 Reversible inhibitor of monoamine oxidase type A......Page 89 Serotonin syndrome......Page 90 3.5 Differences in therapeutic effects of antidepressants......Page 91 4.1 Introduction......Page 95 Acetylcholinesterase inhibitors......Page 96 4.3 Dose and administration......Page 97 Acetylcholinesterase inhibitors......Page 99 Antipsychotic therapy in the care of the older person......Page 100 Concomitant use of cholinesterase inhibitors and memantine......Page 101 Adverse effects and management of memantine......Page 102 5.1 Introduction......Page 107 5.2 Mechanism of action......Page 110 5.3 Dose and administration......Page 111 Lithium......Page 112 Dose and administration of lithium......Page 113 Dose and administration of valproate......Page 114 Dose and administration of carbamazepine......Page 115 Dose and administration of lamotrigine......Page 116 Adverse effects, monitoring and management......Page 117 Adverse effects......Page 118 Lithium toxicity......Page 119 Adverse effects, monitoring and management......Page 121 Adverse effects, monitoring and management......Page 123 Adverse effects, monitoring and management......Page 125 6.1 Introduction......Page 129 Non-benzodiazepine hypnotics......Page 131 Non-benzodiazepine anxiolytics......Page 132 6.3 Dose and administration......Page 134 Adverse effects of benzodiazepines......Page 136 Withdrawal from benzodiazepines......Page 137 Treatment in overdose......Page 138 Z-drugs......Page 139 Precautions and interactions (benzodiazepines and hypnotics)......Page 140 Beta blockers (propranolol)......Page 143 Chapter 1......Page 147 Chapter 2......Page 150 Chapter 3......Page 155 Chapter 4......Page 158 Chapter 5......Page 162 Chapter 6......Page 166 Glossary......Page 169 References......Page 179 Index......Page 191